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Abstract: Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage
(ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in
amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulat-
ing levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of
CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke sub-
jects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according
to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term
(38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels
between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic
features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging
(MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome
had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest
that AQP4 could potentially predict a long-term functional outcome and may play a protective role
after a lobar ICH.
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1. Introduction
Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid in
the walls of cerebral blood vessels [1]. The most common form of CAA is associated with the
accumulation of amyloid-beta (Aβ) peptide in arterioles, capillaries, and leptomeningeal
vessels and is frequently found in Alzheimer’s disease (AD) patients [2,3]. AD is the
most common form of dementia worldwide, whereas CAA is the main cause of lobar
intracerebral hemorrhage (ICH) [4,5]. ICH recurrence is one of the major complications
of CAA, leading to substantial mortality and disability [6]. In addition to symptomatic
ICH, transient focal neurological episodes and cognitive impairment independent of AD
are also common clinical manifestations of CAA [7,8]. Despite the poor prognosis of
CAA-related lobar ICH, no effective treatments are available, and a definitive diagnosis
requires histopathologic demonstration by postmortem autopsy [9,10]. However, in clinical
practice, the diagnosis of CAA is established following the modified Boston criteria based
on clinical data and the presence of specific magnetic resonance imaging (MRI) markers [11].
Lobar cerebral microbleeds, cortical superficial siderosis, enlarged perivascular spaces in
the centrum semiovale, and white matter hyperintensities are some of the frequent CAA
radiological features detected by MRI [12–15].
Pathologically, Aβ peptides are generated by the sequential processing of amyloid
precursor protein (APP) by β-secretase and γ-secretase, resulting in peptides consisting of
40 or 42 amino acids (Aβ40 or Aβ42, respectively). Aβ42 mainly accumulates in neuritic
plaques in the brain parenchyma of AD patients, while Aβ40 is predominantly deposited
on the walls of cerebral vessels, replacing smooth muscle cells and leading to vascular
degeneration in CAA [16,17]. Although the cellular pathways explaining Aβ accumulation
remain unclear, the most widely accepted theory is based on an imbalance between Aβ
production and clearance. Several mechanisms have been described to remove Aβ from
the brain, including proteolytic and microglial degradation, active transport across the
blood–brain barrier (BBB), and perivascular and lymphatic drainage [17–19]. In fact, several
studies have suggested that the perivascular drainage pathway may be impaired in CAA,
which would lead to Aβ accumulation in vascular basement membranes [20–22].
Aquaporins are a family of water channel proteins that regulate water transport
across cell membranes [23]. Aquaporin 4 (AQP4) is the most abundant water channel of
the central nervous system and is mainly expressed by astrocytes and ependymal cells.
AQP4 is highly localized to the perivascular astrocytic end-feet surrounding the glial
limiting membrane of blood vessels [24,25]. Recent evidence suggests that AQP4 plays an
essential role in the clearance of solutes between cerebrospinal fluid (CSF) and interstitial
fluid (IF) through perivascular drainage, including Aβ clearance [26,27]. In this regard,
several studies have described altered AQP4 expression and localization in AD and CAA
patients [28–30]. However, most of these studies are based on postmortem analysis of
human brain tissue, and the alteration of plasma AQP4 levels in AD or CAA patients is still
unexplored. In the present study, we first aimed to study whether circulating AQP4 could
be an indicative biomarker of CAA pathology and whether its determination would thus
contribute to the diagnosis and prognosis of this disease. For this purpose, we analyzed the
potential association of AQP4 levels with the main neuroimaging hallmarks of CAA in a
multicenter cohort of patients with lobar ICH associated with CAA. We next determined the
relationship between circulating AQP4 levels and other functional variables in this cohort.
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2. Methods
2.1. Study Population
The study cohort consisted of 60 patients who presented with symptomatic ICH with
a clinical diagnosis of CAA, as well as 19 age- and sex-matched control subjects. CAA–ICH
patients had possible, probable or probable CAA with a supporting pathology diagnosis
according to the modified Boston criteria [11]. Controls were healthy participants with no
stroke history from the ISSYS (investigating silent strokes in hypertensives, a magnetic
resonance imaging study) cohort who underwent brain MRI at a follow-up visit [31].
Controls were chosen for having no hemorrhagic events on their MRI scans. Sixty CAA–
ICH patients were recruited in the neurology or stroke units from 10 different Spanish
centers. CAA–ICH patients were >55 years old and had suffered at least one lobar ICH.
Patients were excluded if they exhibited any deep intracerebral hemorrhage, presented
microbleeds in the basal ganglia, internal or external capsule, thalamus or brainstem,
or were being treated with anticoagulant therapy. The data obtained from the whole
cohort included patient coding, inclusion date, demographic characteristics (age and
sex), relevant vascular risk factors (hypertension, diabetes, and dyslipidemia), and brain
imaging findings. The clinical and demographic data of both cohorts are shown in Table 1.
Blood samples from the CAA–ICH cohort were obtained in a chronic state of the disease
(13.6 ± 17.8 months after the last ICH) to avoid capturing the initial inflammatory process.
Cognitive impairment was determined at the time of baseline visit (or blood draw) in all
patients based on clinical history and neurological examinations. Additionally, functional
outcome was assessed using the modified Rankin Scale (mRS) for neurologic disability.
For a more detailed analysis, the CAA–ICH cohort was divided into two subcohorts based
on the time point of the last functional outcome evaluation. In subcohort 1 (n = 35), mid-
term outcome was assessed at 12 ± 18.6 months after the last ICH, the same time as
when blood was drawn. In subcohort 2 (n = 25), blood was collected 15.8 ± 17 months
after the last ICH, and long-term outcome was assessed at 34.4 ± 24.8 months after blood
collection. A schematic representation describing the time points of recruitment and
outcome evaluation for these cohorts is shown in Appendix A Figure A1. Outcomes were
dichotomized into good vs. poor: poor outcome was defined as mRS >3, and good outcome
was defined as mRS ≤ 3.
Table 1. Demographic, clinical, and radiological characteristics of the total cohort.
Variable Control(n = 19)
CAA–ICH
(n = 60) p-Value
Age, years, median (IQR) 74 (73.5–74) 76.5 (71.5–70) 0.130
Sex, female, n (%) 10 (52.6%) 30 (50%) 1
Hypertension 19 (100%) 29 (48.3%) 0.000
Diabetes 6 (31.3%) 7 (11.7%) 0.063
Dyslipidemia 16 (78.9%) 17 (28.3%) 0.000
APOE genotype, ε2 carriers 1 (5.3%) 8 (13.3%) 0.679
APOE genotype, ε4 carriers 7 (36.8%) 14 (23.3%) 0.251
Lobar ICH 0 (0.0%) 60 (100%) 0.000
WMH, n (%) 9 (47.4%) 57 (95.0%) 0.000
CMB 0 (0.0%) 40 (66.7%) 0.000
Serum AQP4, ng/mL, median (IQR) 2.12 (1.63–2.67) 2.15 (1.44–4.12) 0.626
CAA, cerebral amyloid angiopathy; IQR, interquartile range; APOE, apolipoprotein E; WMH, white matter
hyperintensity; ICH, intracerebral hemorrhage; CMB, cerebral microbleed; AQP4, aquaporin 4. p-Values below
0.05 are shown in bold.
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The study was approved by the Clinical Investigation Ethics Committee of the Vall
d’Hebron University Hospital, Barcelona, Spain (PR(AG)326/2014), and had the approval
of the ethics committees of all of the participating centers. The study was conducted
in accordance with the Declaration of Helsinki. All patients provided signed informed
consent before inclusion.
2.2. MRI Protocol and Radiological Data
A brain MRI scan was obtained from all participants (1.5 ± 16.4 months after the
last ICH). MRI examinations were acquired using a 1.5-T whole-body scanner system.
The images obtained included axial T2-weighted turbo spin-echo, axial T1-weighted spin-
echo, axial T2-weighted turbo fluid-attenuated inversion recovery (FLAIR), and axial
T2*-weighted echo-planar gradient-echo sequences. All MRI scans were evaluated by the
same neuroradiologist at Hospital Vall d’Hebron, who was blinded to the clinical and
biological information.
The radiological characteristics of the CAA–ICH cohort obtained through MRI analysis
are presented in Table 2. ICHs were defined as hypointense foci on the T2*-weighted
images (diameter >5 mm), and their number and location were recorded. The presence,
number, and distribution of cerebral microbleeds (CMBs; diameter <5 mm) were evaluated
according to the Brain Observer Microbleed Scale [32]. White matter hyperintensities
(WMHs) were defined as hyperintense signal lesions in T2-FLAIR or T2*-weighted images.
Deep and periventricular WMHs were assessed according to the four-point Fazekas rating
scale [33]. This scale scores damage from 0 to 4: (0) Absent or isolated foci of 3 mm,
(1) foci of less than 5 mm (periventricular caps not included); (2) foci of more than 5 mm
(periventricular caps not included); (3) beginning of confluence; (4) large confluent lesions
(larger than 20 mm or two or more lesions merged). Severe WMH was defined as a score of
3 or 4. The WMH score was recorded in the hemisphere not affected by hemorrhage, except
in cases when both hemispheres were involved. Perivascular or Virchow–Robin spaces
are considered CSF-like signal lesions along the course of penetrating arteries. Enlarged
perivascular spaces (EPVS) were counted in the basal ganglia and in the centrum semiovale
(CSO) and were classified as moderate (≤20 EPVS) or severe (≥21 EPVS) according to the
number found on axial T2-weighted MRI images [13,34]. Cortical superficial siderosis (cSS)
was defined as the deposition of hemosiderin in the subpial layers of the cerebral cortex.
The distribution and severity of cSS was categorized as focal (restricted to ≤3 sulci) or
disseminated (>4 sulci) [11]. cSS contiguous to an ICH was not considered. Total cerebral
small vessel disease (SVD) burden defined by Charidimou et al. was assessed using the
principal MRI markers of CAA (lobar CMBs, WMH, EPVS, and cSS) [35]. The total SVD
burden ranged from 0 to 6 points and was determined by counting the presence and grade
of each of these 4 MRI features [35]. In our study, a high SVD burden was defined as a
score ≥4.
2.3. Serum AQP4 Determination
Peripheral blood was collected in EDTA tubes, and serum was immediately separated
by centrifugation at 1500 g for 15 min and stored at –80 ◦C. Only blood samples collected
during a follow-up visit (at least 1.5 months after ICH) were considered for the analysis.
The total AQP4 levels in serum were determined by enzyme-linked immunosorbent assay
(ELISA) using the AQP4 Human Kit (Cusabio Biotech., Wuhan, China) following the
manufacturer’s instructions. Optical density was measured at 450 nm in a Synergy™ Mx
microplate reader (BioTek Instruments Inc., Vermont, USA). All samples were assayed
in duplicate, and replicates with a coefficient of variation >20% were discarded from the
statistical analyses.
2.4. Statistical Analyses
Statistical analyses were conducted with the SPSS 20.0 package (IBM Corporation,
Armonk, NY, USA), and graphs were generated in GraphPad Prism 6 (GraphPad Software,
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La Jolla, CA, USA). Descriptive statistics were used to define the demographic data, clinical
variables, and radiological characteristics of the CAA–ICH cohort. The normality of the
continuous variables was assessed using the Kolmogorov–Smirnov test. For univariate
analysis, the Mann–Whitney U-test and the Kruskal–Wallis test were used to evaluate the
significant differences in the non-normally distributed variables between groups. Corre-
lations were calculated as Spearman’s rho to compare two continuous variables, and the
chi-squared test was used to assess the intergroup differences for the categorical variables.
Binary logistic regression analysis was performed for ≥2 ICHs and cognitive impairment,
including variables significantly associated with each end-point in the univariate analysis.
A stepwise forward method was used in order to select those variables that fitted in the
model. Data are expressed as the mean ± standard error of the mean or median values
(interquartile range). A p-value <0.05 was considered statistically significant.
Table 2. Radiological characteristics of the CAA–ICH cohort.




Probable with supporting pathology 3 (5.0%)
WMH 57 (95.0%)
Periventricular 51 (85.0%)
Moderate (1–2 Fazekas) 10 (16.7%)
Severe (3–4 Fazekas) 41 (68.3%)
Deep subcortical WMH 52 (86.7%)
Moderate (1–2 Fazekas) 21 (35.0%)
Severe (3–4 Fazekas) 31 (51.6%)
CMB 40 (66.7%)





Deep CMB 0 (0.0%)
Cerebellar CMB 4 (6.7%)
EPVS 53 (88.3%)
EPVS basal ganglia 52 (86.7%)
Moderate (1–20) 43 (71.7%)
Severe (21 to >40) 9 (15.0%)
EPVS CSO 41 (68.3%)
Moderate (1–20) 19 (31.7%)





Small vessel disease burden
Low (0–3) 22 (36.7%)
High (4–6) 38 (63.3%)
Data are expressed as n (%).WMH, white matter hyperintensity; CMB, cerebral microbleed; EPVS, enlarged
perivascular space; CSO, centrum semiovale; cSS, cortical superficial siderosis.
3. Results
3.1. Baseline Characteristics
The demographic, clinical, and radiological characteristics of the 60 CAA-related ICH
patients and the 19 healthy control subjects included in the study are described in Table 1.
There were no significant differences between the two groups in terms of age, sex, or APOE
genotype. The control cohort was selected for not having ICH or detectable cerebral
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microbleeds by MRI. Some control subjects did show WMHs in both the periventricular
and deep regions, but the prevalence was significantly higher in CAA-related ICH patients.
AQP4 was detected in the serum from the control subjects and the CAA patients, although
no significant differences were observed between groups.
The main MRI radiological characteristics of the CAA–ICH cohort are summarized in
Table 2. All patients with lobar ICH fulfilled the Boston diagnostic criteria of probable or
possible CAA. The majority of these patients (66.7%) had at least one lobar CMB, whereas
no CMBs in the deep regions were detected. Overall, a high SVD burden score (63.3%),
a high prevalence of severe WMH in the periventricular (68.3%) and deep regions (51.6%),
a high degree of EPVS-CSO (36.7%), and disseminated cSS (35%) constituted the principal
radiological features of the cohort.
3.2. AQP4 Levels According to Clinical and Radiological Characteristics
Circulating levels of AQP4 were evaluated in the CAA-related ICH cohort and ana-
lyzed for any correlations with the clinical and radiological characteristics. We determined
that lower circulating levels of AQP4 were related to Apoε4 and cognitive impairment in
the univariate analysis (Table 3). However, only the presence of WMH in the periventricular
areas remained independently associated with cognitive impairment after the adjustment
by binary logistic regression analysis (Table A1 and Table 5). On the contrary, patients who
had suffered a previous hemorrhagic stroke presented significantly lower levels of AQP4,
whereas presenting a previous ischemic stroke did not result in changes in serum AQP4
levels (Table 3).
Table 3. Univariate analysis of AQP4 levels according to CAA–ICH demographic and clinical characteristics.
Variable YES NO p-Value
Age r = 0.147 0.264
Sex, female 2.19 (1.46–4.20)n = 30
2.08 (1.41–4.04)
n = 30 0.684
Hypertension 1.85 (1.45–3.29)n = 29
2.89 (1.77–4.27)
n = 28 0.102
Diabetes 2.60 (2.11–3.58)n = 7
2.14 (1.44–4.27)
n = 48 0.435
Dyslipidemia 1.81 (1.41–2.89)n = 17
2.11 (1.44–4.41)
n = 36 0.331
APOE genotype, ε2 carriers 1.75 (1.18–3.00)n = 8
2.30 (1.45–4.27)
n = 52 0.317
APOE genotype, ε4 carriers 1.46 (1.03–2.60)n = 14
2.41 (1.65–4.20)
n = 46 0.028
Cognitive impairment 1.69 (1.27–2.76)n = 30
3.09 (1.81–4.38)
n = 30 0.030
Previous stroke 1.28 (0.99–1.67)n = 12
2.68 (1.69–4.35)
n = 48 0.002
Previous ischemic stroke 1.53 (1.26–3.27)n = 4
2.68 (1.69–4.35)
n = 48 0.261
Previous hemorrhagic stroke 1.12 (0.79–1.61)n = 8
2.68 (1.69–4.35)
n = 48 0.001
Data are expressed as median nanograms per mililiter (interquartile range). r, Spearman’s rho correlation,
CAA–ICH cohort; n = 60. p-Values below 0.05 are shown in bold.
The neuroimaging analysis of the CAA–ICH cohort revealed a negative correlation
between the number of lobar ICHs and AQP4 serum levels (Table 4). In fact, those patients
with ≥2 lobar ICHs had significantly lower levels of AQP4 than those with only one lobar
ICH (Figure 1A). After adjustment for significantly associated variables in the univariate
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analysis (Table 5), the logistic regression analysis confirmed that serum AQP4 levels,
Apoε2 allele, high SVD burden, and atrophy were independent predictors of ≥2 lobar
ICHs (Table 5). In addition, a tendency (p = 0.052) toward lower AQP4 levels in patients
presenting lobar CMBs was detected. When this variable was reclassified, serum samples
from patients presenting with ≥5 CMBs showed lower AQP4 levels (Figure 1B). CAA–ICH
patients presenting WMHs in deep regions also had significantly lower levels of AQP4
(Table 4). Remarkably, we did not detect an association between serum AQP4 concentration
and the total MRI small vessel disease score validated for a pathological CAA presentation
with symptomatic ICH [35].
Table 4. Univariate analysis of AQP4 levels according to CAA–ICH radiological characteristics.
Variable YES NO p-Value
Interval between the last ICH and
the date of blood collection r = –0.052 0.703
Number of lobar ICHs r = –0.307 0.017
WMH 2.04 (1.43–3.71)n = 57
4.46 (3.15–5.7)
n = 3 0.163
Periventricular 2.02 (1.42–3.69)n = 51
3.29 (1.84–5.02)
n = 9 0.092
Deep subcortical WMH 1.88 (1.42–3.67)n = 50
3.41 (2.04–5.19)
n = 10 0.045
Lobar CMB 1.83 (1.41–3.79)n = 40
2.84 (1.93–4.25)
n = 20 0.052
EPVS 2.26 (1.46–4.04)n = 53
1.81 (1.27–3.78)
n = 7 0.718
EPVS basal ganglia 2.30 (1.47–4.12)n = 52
1.63 (1.27–3.78)
n = 8 0.521
EPVS CSO 2.45 (1.50–4.36)n = 41
1.84 (1.10–3.00)
n = 19 0.144
cSS 2.11 (1.16–4.38)n = 30
2.15 (1.65–2.90)
n = 30 0.988
Chronic Infarct 1.53 (1.27–2.02)n = 13
2.52 (1.55–4.19)
n = 44 0.146
Atrophy 2.26 (1.43–4.00)n = 23
2.04 (1.50–4.04)
n = 37 0.715
High SVD burden (score 4–6) 2.35 (1.27–4.34)n = 23
2.03 (1.81–2.90)
n = 37 0.570
Data are expressed as median nanograms per mililiter (interquartile range). r, Spearman’s rho correlation.
CAA–ICH cohort: n = 60. ICH, intracerebral hemorrhage; WMH, white matter hyperintensity; CMB, cerebral
microbleed; EPVS, enlarged perivascular space; CSO, centrum semiovale; cSS, cortical superficial siderosis; SVD,
small vessel disease burden. p-Values below 0.05 are shown in bold.
3.3. AQP4 and Functional Outcome
We next studied the association between circulating AQP4 levels and functional outcome
in two subcohorts divided according to the evaluation time point (Appendix A Figure A1).
A poor outcome was assessed in seven (20%) of the 35 patients from subcohort 1 and in
eight (32%) of the 25 patients from subcohort 2. No statistically significant differences were
found in the levels of AQP4 between subcohort 1 (1.87 (1.29–3.53) ng/mL) and subcohort
2 (2.38 (1.65–4.38) ng/mL) (p = 0.165). Interestingly, we found that AQP4 levels differed
among CAA–ICH patients depending on the time when the outcome was assessed. First,
in subcohort 1, when patient serum was obtained in parallel to the functional outcome
evaluation, AQP4 levels did not differ between patients classified with good and poor
outcomes (Figure 2A). In contrast, when the long-term functional outcome was assessed,
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those CAA–ICH subjects showing good outcomes presented significantly higher levels
of AQP4 than subjects with a poor outcomes and controls (Figure 2B). In subcohort 2,
AQP4 was the only variable associated with poor outcome in the univariate analysis
(Appendix A Table A2).
Figure 1. Association between AQP4 levels and hemorrhagic events in the CAA–ICH cohort. (A) Box-
plot distribution according to the number of symptomatic ICHs (1 ICH, n = 43; ≥2 ICH, n = 17).
(B) Boxplot distribution according to the number of lobar CMBs (<5 CMB, n = 34; ≥5 CMB, n = 26).
ICH, intracerebral hemorrhage; CMB, cerebral microbleed.
Table 5. Binary logistic regression for cognitive impairment and ≥2 ICHs.
Regression Cognitive Impairment Regression ≥ 2 ICHs
Variable OR (95% CI) p-value OR (95% CI) p-value
AQP4 - 0.520 (0.286–0.976) p = 0.042
APOE genotype, ε2 carriers - 22.536 (1.989–255.296) p = 0.034
WMH periventricular 10.545 (1.227–90.662) p = 0.032 -
Atrophy - 6.167 (1.080–35.213) p = 0.004
High SVD burden (score 4–6) - 11.280 (1.109–114.739) p = 0.025
Binary logistic regression analysis was performed with variables associated with cognitive impairment and/or ≥2 ICHs in univariate
analysis. The results are given as odds ratios (ORs) with 95% confidence intervals (CIs) and p-values. SVD, small vessel disease. p-Values
below 0.05 are shown in bold.
Figure 2. Association between AQP4 levels and functional neurological outcomes in the CAA–ICH
cohort. (A) Boxplot distribution between good (n = 27) and poor (n = 7) mid-term functional outcomes
(CAA–ICH subcohort 1) compared to controls (n = 19). (B) Boxplot distribution between good (n = 17)
and poor (n = 8) long-term functional outcomes (CAA–ICH subcohort 2) compared to controls (n = 19).
Outcomes were dichotomized into good vs. poor, and good outcomes were predefined as 0–3 on
the modified Rankin Scale for Neurologic Disability. ICH, intracerebral hemorrhage; CMB, cerebral
microbleed. * p < 0.05.
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4. Discussion
In this study, we have shown for the first time the presence of AQP4 in the circulation
in CAA-related ICH patients. Although no significant differences were found in circulating
AQP4 levels between CAA–ICH patients and controls, an association between serum
AQP4 levels and cerebral hemorrhagic load in the CAA cohort was detected. Furthermore,
our data revealed that AQP4 could predict the long-term functional outcome in CAA
patients after lobar ICH.
Interest in AQP4 research has grown considerably over the last few years. AQP4 is
the most highly expressed aquaporin in the brain and is involved in the maintenance of
the brain water balance under physiological and pathological conditions [24,29]. Several
studies have demonstrated its implication in cerebral edema, ischemic stroke, traumatic
brain injury, tumors, and neuromyelitis optica, among others [24,28,35]. Various studies
have also found that AQP4 is necessary for the clearance of interstitial solutes, including Aβ,
through the glymphatic system, suggesting a potential role of AQP4 in the physiopathology
of AD and/or CAA [26,36].
To date, the vast majority of studies exploring the role of AQP4 in AD and CAA
patients have described an altered distribution of this protein in diseased postmortem brain
tissues. Wilcock et al. found reduced AQP4 expression in AD patients with moderate or
severe CAA [37]. However, subsequent studies have demonstrated an increase in AQP4
immunoreactivity in AD and CAA brains compared with controls [38–40]. In particular,
it was suggested that the AQP4 expression pattern could differ depending on the disease
stage, with increased AQP4 immunodetection in CAA cases with the highest AD score [41].
In agreement with that, it has recently been described that the pattern of AQP4 immun-
odetection is different in gray matter compared to white matter and that it changes with
age and with the severity of CAA [42]. Taking all of this into account, AQP4 expression in
the brain may be associated with different factors, such as age, CAA severity, and specific
neuroanatomical area. However, to the best of our knowledge, no studies have reported
the modulation of AQP4 levels in the circulation in AD or CAA.
In this regard, we were able to detect AQP4 in serum from CAA-related ICH patients,
although the levels did not differ from those in non-stroke control subjects. In agreement
with previous studies [43,44], our results revealed that the presence of WMH in periventric-
ular areas was also independently associated with cognitive impairment in the CAA–ICH
cohort. In addition, we found lower circulating levels of AQP4 in patients with cognitive
impairment in the univariate analysis. This result is aligned with findings in preclinical
models, where behavioral tests revealed a cognitive deficit in AQP4 knockout mice [45–47].
Indeed, studies performed in AD and CAA transgenic mouse models have confirmed that
AQP4 deletion promotes cognitive deficits and increases Aβ accumulation and synaptic
damage, suggesting a possible contribution of AQP4 to Aβ clearance through the brain
vasculature [48]. In contrast to these results, in a recent study conducted in 5xFAD mice,
an accelerated model of AD with a lower vascular damage contribution, AQP4 deficiency
did not induce alterations in Aβ accumulation or in memory deficit [49]. Nevertheless,
experimental evidence suggests that AQP4 may be involved in the clearance of Aβ through
perivascular drainage, thus playing a potential protective role in CAA pathology. However,
in our study, we did not find an association between circulating AQP4 levels and the global
SVD neuroimaging burden score, which has been associated with pathological CAA [35,50].
This result suggests that circulating AQP4 is not an indicative biomarker of CAA pathology.
All the same, because AQP4 is related to solute clearance, further research should focus on
studying AQP4 protein levels in CSF [26,27].
Remarkably, we found a clear association between serum AQP4 levels and CAA-
related hemorrhagic lesions, including symptomatic ICH and CMBs, in the study cohort.
Indeed, CAA–ICH patients presenting ≥2 ICHs and/or ≥5 lobar CMBs had lower levels
of AQP4 than those patients without those hemorrhagic events, suggesting a potential
protective role of this protein. Moreover, we demonstrated a negative correlation between
the number of lobar ICHs and AQP4 serum levels, which is in agreement with other studies
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where AQP4 deletion worsened the neurological impairment and promoted neuronal death
after ICH [51,52]. Indeed, AQP4 genomic variants were recently found to be independent
predictors of the outcome after ICH in different populations [53,54]. Furthermore, we found
that circulating AQP4 levels, together with the Apoε2 allele, atrophy, and high SVD burden
variables, were independent predictors of presenting ≥2 ICHs. In this line, the Apoε2 allele
is a well-known risk factor for ICH attributed to CAA, predisposing patients to recurrent
bleeding [55–57]. Due to the specific localization of AQP4 at the astrocyte end-feet, it has
been suggested that AQP4 could play a role in maintaining the BBB integrity [58]. Although
most studies seem to point to a protective role for AQP4, it is still controversial whether
AQP4 deletion alters the integrity of the BBB after ICH [59–62]. Further studies are needed
to confirm the exact function of AQP4 in the brain following ICH, and our findings should
be expanded to other cohorts presenting with ICH independently of a CAA etiology.
The present study also revealed that the analysis of serum AQP4 could potentially
predict a long-term functional outcome in CAA–ICH patients. Our results showed that
patients with a good long-term functional outcome presented higher circulating levels of
AQP4 than patients with poor outcomes or healthy controls. In this area, we are aware of
only one study that analyzed the levels of AQP4 in the circulation in neurological disorders,
reporting higher levels of AQP4 in ischemic stroke patients after the acute phase of the
disease [63]. Furthermore, in this same study, AQP4 was found to be an independent
predictor of good neurological outcome in stroke patients, which is in agreement with
our results [63]. Overall, the increase in circulating AQP4 levels in CAA–ICH patients
presenting good long-term outcome and the decreased AQP4 levels in patients with a
higher cerebral hemorrhagic load provide suggestive evidence of the potentially protective
role of AQP4 after ICH.
Our study has some limitations. First, the sample size was relatively small, which
could mask some associations not detectable after multiple testing corrections. Other limita-
tions include the cross-sectional design of the study and the differences in the time points of
the recruitment and functional outcome evaluation after the hemorrhagic episode. For this
last reason, we decided to divide the total cohort into two subgroups, reducing the sample
size even more. Taking all of this into consideration, further research should focus on
larger patient cohorts with functional evaluation at different time points to explore whether
our findings could be useful for the clinical prediction of long-term functional outcome in
ICH patients. It would also be interesting to study the temporal profile of AQP4, as well
as to evaluate the association between circulating AQP4 levels and the progression of
neuroimaging markers with a follow-up blood draw and an MRI examination at different
time points.
5. Conclusions
This study demonstrated, for the first time, that AQP4 can be detected in serum
samples from CAA-related lobar ICH patients. Our data showed an association between
circulating AQP4 levels and specific hemorrhagic neuroimaging features. In particular,
we observed a decrease in AQP4 levels in patients presenting with more than two symp-
tomatic lobar ICHs and in patients with more than five lobar CMBs detected by MRI.
These findings suggest that AQP4 could play a protective role in CAA patients after ICH,
potentially preserving BBB functionality, which could provide a possible therapeutic target
for this pathology. Furthermore, because we found that circulating APQ4 levels were higher
in those patients presenting a good long-term outcome, analysis of this serum biomarker
might be considered an interesting candidate to be further investigated to improve the
accuracy of the outcome prognosis in patients presenting with lobar ICH.
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Appendix A
Figure A1. Schematic representation of the cerebral amyloid angiopathy (CAA)–intracerebral hemor-
rhage (ICH) cohort according to the functional outcome evaluation time point. (A) Summary table
of the time intervals in the two subcohorts. (B) CAA–ICH subcohort 1 refers to individuals whose
functional outcome was assessed at the blood collection date, 12 ± 18.6 months after the last ICH
(mid-term outcome). (C) CAA–ICH subcohort 2 refers to individuals in which functional outcome
was assessed 34.4 ± 24.8 months after the blood collection date (long-term outcome). Months are
expressed as mean ± SD (standard deviation). Parts of this figure were supported by Servier Medical
Art with permission under the Creative Commons Attribution 3.0 Unported License.
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Table A1. Univariate analysis of the variables associated with cognitive impairment and ≥2 ICHs.
Cognitive impairment ≥2 ICHs
Variable YES NO p-value YES NO p-Value
AQP4 1.69 (1.27–2.76)n = 30
3.09 (1.81–4.38)




n = 43 0.026
Age 77 (73–79) 74 (69–79) 0.406 77 (72–78) 76 (71.5–79) 0.941
Sex, female 18 (60.0%) 12 (40.0%) 0.196 10 (58.8%) 20 (46.5%) 0.567
Hypertension 15 (53.6%) 14 (48.3%) 0.793 10 (66.7%) 19 (45.2%) 0.230
Diabetes 4 (14.3%) 3 (11.1%) 1 2 (14.3%) 5 (12.2%) 1
Dyslipidemia 8 (29.6%) 9 (34.6%) 0.773 8 (53.3%) 9 (23.7%) 0.053
APOE genotype, ε2 carriers 4 (13.3%) 4 (13.3%) 1 5 (29.4%) 3 (7.0%) 0.035
APOE genotype, ε4 carriers 10 (33.3%) 4 (13.3%) 0.125 6 (35.3%) 8 (18.6%) 0.190
Cognitive impairment - - - 9 (52.9%) 21 (48.8%) 1
≥2 lobar ICHs 9 (30.0%) 8 (26.7%) 1 - - -
WMH 29 (96.7%) 28 (93.3%) 1 17 (100%) 40 (93.0%) 0.551
Periventricular 29 (96.7%) 22 (73.3%) 0.026 14 (82.4%) 37 (86.05%) 0.704
Deep subcortical WMH 28 (93.3%) 22 (73.3%) 0.080 15 (88.2%) 35 (81.4) 0.709
Lobar CMB 21 (70.0%) 19 (63.3%) 0.785 13 (76.5%) 27 (62.8%) 0.375
EPVS 25 (83.3%) 28 (93.3%) 0.424 13 (76.5%) 40 (93.0%) 0.092
EPVS basal ganglia 25 (83.3%) 27 (90.0%) 0.706 12 (70.6%) 40 (93.0%) 0.035
EPVS CSO 19 (63.3%) 22 (73.3%) 0.580 11 (64.7%) 30 (69.8%) 0.763
cSS 18 (60.0%) 12 (40.0%) 0.196 13 (76.5%) 17 (39.5%) 0.020
Chronic infarct 10 (33.3%) 3 (11.1%) 0.061 5 (33.3%) 8 (19.0%) 0.294
Atrophy 13 (43.3%) 10 (33.3%) 0.596 12 (70.6%) 11 (25.6%) 0.003
High SVD burden (score 4–6) 21 (55.53%) 17 (44.7%) 0.422 15 (88.2%) 23 (53.5%) 0.017
AQP4, aquaporin 4; ICH, intracerebral hemorrhage; APOE, apolipoprotein E; WMH, white matter hyperintensity; CMB, cerebral microbleed;
EPVS, enlarged perivascular space; CSO, centrum semiovale; cSS, cortical superficial siderosis; SVD, small vessel disease. p-Values below
0.05 are shown in bold.
Table A2. Univariate analysis for long-term functional outcome in subcohort 2.
CAA–ICH subcohort 2 (n = 25)
Variable Poor outcome Good outcome p-Value
AQP4 1.56 (1.42–1.81)n = 8
4.20 (2.33–4.89)
n = 17 0.002
Age 77 (74.5–81) 77 (72–79) 0.549
Sex, female 6 (75.0%) 9 (52.9%) 0.294
Hypertension 3 (42.9%) 11 (64.7%) 0.324
Diabetes 1 (14.3%) 4 (25.7%) 0.519
Dyslipidemia 2 (25.0%) 1 (7.7%) 0.271
APOE genotype, ε2 carriers 1 (12.5%) 2 (11.8%) 0.958
APOE genotype, ε4 carriers 2 (25.0%) 3 (17.5%) 0.668
Cognitive impairment 6 (75%) 6 (35.3%) 0.064
≥2 lobar ICHs 3 (37.5%) 3 (17.6%) 0.278
WMH 8 (100%) 16 (94.1%) 0.484
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Table A2. Cont.
CAA–ICH subcohort 2 (n = 25)
Variable Poor outcome Good outcome p-Value
Periventricular 8 (100%) 13 (76.5%) 0.134
Deep subcortical WMH 8 (100%) 12 (70.6%) 0.086
Lobar CMB 7 (87.5%) 10 (58.8%) 0.152
EPVS 8 (100%) 17 (100%) -
EPVS basal ganglia 7 (87.5%) 17 (100%) 0.137
EPVS CSO 8 (100%) 15 (88.2%) 0.312
cSS 3 (37.5%) 9 (52.9%) 0.471
Chronic Infarct 3 (42.9%) 2 (11.8%) 0.088
Atrophy 3 (37.5%) 6 (35.3%) 0.915
High SVD burden (score 4–6) 4 (50.0%) 10 (58.8%) 0.678
AQP4, aquaporin 4; ICH, intracerebral hemorrhage; WMH, white matter hyperintensity; CMB, cerebral mi-
crobleed; EPVS, enlarged perivascular space; CSO, centrum semiovale; cSS, cortical superficial siderosis; SVD,
small vessel disease. p-Values below 0.05 are shown in bold.
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